Store launching soon — browse the catalog and join the waitlist to be notified at launch.
✦USPS Priority Mail1–3 day delivery across the U.S.Free on orders over $200
Store launching soon — browse the catalog and join the waitlist to be notified at launch.
Your cart is empty
Long-Acting GHRH Analogue
Also known as CJC-1295 DAC / hGRF(1-29) bioconjugate
CJC-1295 with DAC is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) bearing a Drug Affinity Complex that extends its half-life, studied in research on the GH/IGF-1 axis.
🚀 Launching soon — join the waitlist to be notified when this product is available.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
CJC-1295 with DAC is a synthetic analogue of growth-hormone-releasing hormone (GHRH 1-29) bearing a Drug Affinity Complex that extends its half-life, studied in research on the GH/IGF-1 axis.
Experimental models examine prolonged GHRH-receptor stimulation and downstream secretory dynamics.
Third-party tested for purity, ID, quantity.
CJC-1295 with DAC couples a tetrasubstituted GHRH(1-29) analogue to a maleimide group that binds serum albumin, markedly prolonging its circulating half-life. Research has examined sustained stimulation of growth-hormone and IGF-1 secretion in controlled studies.
Investigations evaluate the kinetics of GH release and IGF-1 elevation under structured experimental conditions.
CJC-1295 was developed from research into albumin-binding bioconjugates designed to extend the activity of short-lived GHRH peptides.
Early clinical pharmacology characterized its prolonged stimulation of the GH/IGF-1 axis, distinguishing the DAC-bearing form from shorter-acting analogues.
Research into CJC-1295 with DAC focuses on GHRH-receptor signaling and GH/IGF-1 axis kinetics. Frameworks evaluate albumin-binding half-life extension and secretory dynamics under controlled clinical and preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of cjc 1295 with dac. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
PubMedOnce-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
PubMedPulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
PubMedRelated
Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
From$50.00
$60.00
Small molecule studied for metabolic regulation, NAD pathways, and cellular energy signaling
From$40.00
Dual peptide complex studied for actin signaling, tissue regeneration pathways, and recovery system research
From$80.00
Oral peptide format studied for systemic repair signaling and gastrointestinal pathway research
$140.00
